Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-2 NASH IS IMPROVED THROUGH MODIFICATIONS IN H3K9 METHYLATION BY PIRFENIDONE AC...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P-2 NASH IS IMPROVED THROUGH MODIFICATIONS IN H3K9 METHYLATION BY PIRFENIDONE ACTING AS JMJD2B DEMETHYLASE ANTAGONIST.
Visits
192
Samael Rodríguez1, Rebeca Rosas1, Angel Omar Vazquez1, Ivonne Palacios2, Ricardo De la Rosa1, Rebeca Escutia1, Josep Jiménez2, Luis Felipe Jave3, Arturo Santos4, Ana Sandoval1, Juan Armendariz1
1 Biología Molecular y Genómica, Universidad de Guadalajara, Guadalajara, México
2 Biochemistry and Physiology, Universitat de Barcelona, Barcelona, España
3 Inmunología, IMSS/CIBO, Guadalajara, México
4 EMCS, Tecnológico de Monterrey, Guadalajara, México
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

NASH is characterized by hepatic lipid accumulation and inflammation and Jmjd2b up-regulation has been linked with this illness progression. Pirfenidone is an antifibrotic agent with anti-inflammatory and antioxidant effects recognized to decrease NASH features. Here, we report epigenetics mechanisms related to PFD-induced histone modifications involved in experimental NASH. This study aimed to investigate PFD as an epigenetic regulator in the Jmjd2b pathway by demethylating H3k9me3 in a NASH animal model.

Material and Methods

Male C57BL/6J mice were fed with either normo-diet, or high fat/carbohydrate-containing diet (HF) for 16 weeks. A HF-subgroup was treated with PFD 300 mg/kg/d from week 8th to the end of protocol. Weight was recorded on weekly basis. Insulin tolerance test was performed at the end of treatment. Dual channel microarrays were hybridized to the Mus musculus genome version with 22,000 genes using hepatic mRNAs. Liver and fat histological analyses were carried out, and liver proteins were analyzed by western blot and Chromatin immunoprecipitation (ChIP). Molecular docking was used to validate binding of PFD to JMJD2BBBBB.

Results

Compared with HF group, mice treated with PFD reduced weight gain, hepatic fat accumulation, and epididymal fat. In addition, treatment drastically decreased cholesterol, triglycerides and VLDL, ALT and AST. Inflammatory nodules, fibrosis, and steatosis in liver tissue were also reduced. Besides, PFD modified expression of genes, such as, Jmjd2b, Pparg, Fasn and Srebp1. Likewise, PFD restored the repressive marks in H3k9, suggesting its capacity as an epigenetic regulator by decreasing Jmjd2b protein activity and interacting with its catalytic site (JmjC).

Conclusions

PFD played an important role as an epigenetic regulator modifying Jmjd2b activity and improving NASH features.

Full text is only aviable in PDF
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos